The story has been updated to include comments from company officials from its conference call.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exact Sciences today reported a 23 percent drop in revenues year over year while its net loss more than doubled during the first quarter.

The Madison, Wis.-based molecular diagnostics firm said that for the three months ended March 31, revenues came in at $1 million, down from $1.3 million a year ago and short of analyst expectations of $1.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.